Breast cancer Posts on Medivizor

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Posted by Medivizor on May 8, 2022 in Breast cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Posted by Medivizor on Apr 26, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the oncological effectiveness of intraoperative radiotherapy (IORT) and whole breast irradiation (WBI) for patients with early breast cancer (BC). This study concluded that there was a high oncological effectiveness for both groups of patients. Some background Intraoperative...

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Posted by Medivizor on Apr 14, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that...

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Posted by Medivizor on Apr 10, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness of adding ribociclib (Kisqali) to endocrine (hormone) therapy in pre-/perimenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding ribociclib to hormone therapy significantly improved survival outcomes than hormone...

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Posted by Medivizor on Apr 3, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICI) plus chemotherapy versus chemotherapy alone for the treatment of patients with triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was more effective than chemotherapy alone and was associated with a higher rate of side...

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Posted by Medivizor on Mar 20, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk factors associated with acute radiation dermatitis (ARD; skin irritation) after radiotherapy (RT) in patients with breast cancer (BC). The data showed that patients with diabetes, smokers, and those with a body mass index (BMI; a measure of body weight in relation to height) of more than 25 kg/m2 had a...

Vacations for Adult Cancer Patients: Update

Posted by Peigi Chace on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Posted by Medivizor on Feb 25, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of trilaciclib (Cosela) given before gemcitabine (Gemzar) plus capecitabine (Xeloda) (GC) chemotherapy regimen in patients with metastatic triple-negative breast cancer (mTNBC). The data showed that trilaciclib given before GC chemotherapy regimen was effective and significantly improved overall...

Evaluating the effects of physical therapies on improvement in psychosomatic symptoms and quality of life in patients with breast cancer treated with aromatase inhibitors.

Posted by Medivizor on Feb 13, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effects of physical therapies on improvement in psychosomatic symptoms and quality of life (QoL) in patients with breast cancer (BC) treated with aromatase inhibitors (AIs). The data showed that acupuncture can significantly reduce pain intensity and exercise training might improve QoL in these...

Evaluating the long-term outcome of using gonadotropin-releasing hormone agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer.

Posted by Medivizor on Jan 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of using gonadotropin-releasing hormone (GnRH) agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer (BC). The data showed that GnRH agonist use during chemotherapy was safe and effective to preserve ovarian function in these...

Evaluating the effectiveness of adding immunotherapy to chemotherapy for metastatic triple-negative breast cancer.

Posted by Medivizor on Jan 9, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of adding immunotherapy (IT) to chemotherapy (CT) for the treatment of patients with metastatic triple-negative breast cancer (TNBC). The data showed that the addition of IT to CT significantly improved survival without cancer worsening. However, IT plus CT combination did not...

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by Medivizor on Jan 9, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities)...

Breast cancer Posts on Medivizor

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Vacations for Adult Cancer Patients: Update

Evaluating the effectiveness of trilaciclib given before chemotherapy in patients with metastatic triple-negative breast cancer.

Evaluating the effects of physical therapies on improvement in psychosomatic symptoms and quality of life in patients with breast cancer treated with aromatase inhibitors.

Evaluating the long-term outcome of using gonadotropin-releasing hormone agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer.

Evaluating the effectiveness of adding immunotherapy to chemotherapy for metastatic triple-negative breast cancer.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Categories

Recent Posts

Archives

Breast cancer Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email